regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The disease-modifying treatments have several adverse effects. One of the most common is irritation at the injection site for glatiramer acetate and the interferons (up to 90% with subcutaneous injections and 33% with intramuscular injections). Over time, a visible dent at the injection site, due to the local destruction of fat tissue, known as lipoatrophy, may develop. Interferons may produce flu-like symptoms; some people taking glatiramer experience a post-injection reaction with flushing, chest tightness, heart palpitations, and anxiety, which usually lasts less than thirty minutes. More dangerous but much less common are liver damage from interferons, systolic dysfunction (12%), infertility, and acute myeloid leukemia (0.8%) from mitoxantrone, and progressive multifocal leukoencephalopathy occurring with natalizumab (occurring in 1 in 600 people treated). Fingolimod may give rise to hypertension and slowed heart rate, macular edema, elevated liver enzymes, or a reduction in lymphocyte levels. Tentative evidence supports the short-term safety of teriflunomide, with common side effects including headaches, fatigue, nausea, hair loss, and limb pain. There have also been reports of liver failure and PML with its use and it is dangerous for fetal development. Most common side effects of dimethyl fumarate are flushing and gastrointestinal problems. While dimethyl fumarate may lead to a reduction in the white blood cell count there were no reported cases of opportunistic infections during trials.
== Antideuterium and the antideuteron == An antideuteron is the antimatter counterpart of the deuteron, consisting of an antiproton and an antineutron. The antideuteron was first produced in 1965 at the Proton Synchrotron at CERN and the Alternating Gradient Synchrotron at Brookhaven National Laboratory. A complete atom, with a positron orbiting the nucleus, would be called antideuterium, but as of 2019 antideuterium has not yet been created. The symbol used for antideuterium is D, that is, D with an overbar.
== Products == There are four serving sizes. Also offered are milkshakes and smoothies, among them the Cold Stone PB&C; Its large size was designated by Men's Health Magazine as the most unhealthy drink in the United States for two consecutive years. The drink has 2,010 calories, 131 grams of fat with 68 grams saturated fat, and 153 grams of sugar. Cold Stone Creamery: Scoop It Up, a simulation video game developed by CyberPlanet Interactive and published by Zoo Games, was released for the Wii in 2009.
Sources: en.wikipedia.org
Density: Liquid: 162.4 kg/m3 Gas: 0.452 kg/m3 Liquefied 2H2O: 1105.2 kg/m3 at STP Viscosity: 12.6 μPa·s at 300 K (gas phase) Specific heat capacity at constant pressure cp: Solid: 2950 J/(kg·K) Gas: 5200 J/(kg·K)
== Overdose == Gastric decontamination measures such as activated charcoal are sometimes recommended in cases of overdose. The symptoms are usually indicative of CNS depression (or conversely CNS stimulation in some) and excess anticholinergic side effects. The LD50 in mice is 123 mg/kg and 295 mg/kg in rats.
In 2011, Antonio Lombatti noted several of these visual impossibilities in the body, such as the right footprint wrongly depicted in the shroud, and the locks of hair printed at the same height as the face, as if they were a solid structure, instead of resting on the ground. Lombatti further commented that the pressure from the body lying on the sheet should have caused the back image to be darker than the front image, which does not happen in the depiction of the shroud. The way the blood flows in rivulets from the head without mixing with the hair also struck him as more artistic than realistic. In 2018 an experimental Bloodstain Pattern Analysis (BPA) was performed to study the behaviour of blood flows from the wounds of a crucified person, and to compare this to the evidence on the Turin Shroud. The comparison between different tests demonstrated that the blood patterns on the forearms and on the back of the hand are not connected, and would have had to occur at different times, as a result of a very specific sequence of movements. In addition, the rivulets on the front of the image are not consistent with the lines on the lumbar area, even supposing there might have been different episodes of bleeding at different times. These inconsistencies suggest that the Turin linen was an artistic or didactic representation, rather than an authentic burial shroud.
=== Draft and minor leagues === The Boston Red Sox selected Bagwell in the fourth round (110th overall) of the 1989 Major League Baseball draft. Throughout his career, Barry Axelrod served as his agent. For his first professional assignment, the Red Sox appointed Bagwell to the Single-A Winter Haven Red Sox of the Florida State League in 1989, where he batted .310 with two home runs. In 1990, while playing for the Double-A New Britain Red Sox, Bagwell won the Eastern League Most Valuable Player Award. In 136 games with New Britain, he batted .333 with 160 hits, four home runs (HR), 61 runs batted in (RBI), 34 doubles, seven triples, 73 bases on balls (BB or walks), 57 strikeouts (SO), .422 on-base percentage (OBP), .457 slugging percentage (SLG) and .880 on-base plus slugging percentage (OPS). He finished first in the league in hits and doubles, second in batting, OBP and OPS, fourth in walks, fifth in SLG, ninth in runs scored and tenth in RBI. Late in the 1990 season, the Red Sox, who were in search of relief pitching to improve their chances of making the playoffs, contacted the Houston Astros about Larry Andersen. Stan Benjamin, who scouted the New England region for the Astros, recommended that they ask for Bagwell in return. The Astros initially hesitated owing to his sparse home run production, but Benjamin persuaded them, quipping that New Britain's Beehive Field was so large that "Babe Ruth couldn't hit home runs in that ballpark."[a] On August 30, 1990, the Red Sox took the Astros' offer.
Sources: en.wikipedia.org
Bruce Randall Donald (born 1958) is an American computer scientist and computational biologist. He is the James B. Duke Professor of Computer Science and Biochemistry at Duke University. He has made numerous contributions to several fields in Computer Science such as robotics, Microelectromechanical Systems (MEMS), Geometric & physical algorithms and computational geometry, as well as in areas of Structural Molecular Biology & Biochemistry such as Protein design, Protein Structure Determination and Computational Chemistry.
The caesium, precipitated with ferric ferrocyanide (Prussian blue) would be the only waste requiring special burial sites. The aim is to get annual exposure from the contaminated environment down to 1 millisievert (mSv) above background levels. The most contaminated area where radiation doses are greater than 50 mSv/year must remain off-limits, but some areas that are currently less than 5 mSv/year may be decontaminated, allowing 22,000 residents to return.
planets in the habitable zones of stars with low metallicity are the best targets to search for complex life on land." A university reports a study (29 Mar) affirming the high level of economic losses from biological invasions, showing they have risen to the level of economic damage costs from floods or earthquakes, which are also rising. 19 April A bolide is observed over Ukraine and Belarus for about five seconds. It is first observed at an altitude of 98 km above Velyka Dymerka, then passes directly above Kyiv at an altitude of 80 km and continues to the southwest with a speed of 29 km/s. A bright flare occurs at an altitude of 38 km, when the bolide's absolute magnitude reaches approximately −18. The likely cause of grey hair is shown to be pigment-making cells losing their ability to mature into melanocytes. Researchers show parrots can and enjoy to use a videocalling system. A study with mice shows that microplastics pass the blood–brain barrier (BBB), entering and accumulating in the brain, and identifies a key determinant for whether or not they pass the BBB. 20 April A new 29-year record of ice sheet mass in Greenland and Antarctica is published as part of the IMBIE collaboration. It finds that the combined ice loss in these regions has more than tripled since the early 1990s, with 2019 seeing the greatest losses of any year on record. These findings have implications for future sea level rise.
Na = nitrogen absorbed in proteins on the test diet Nr = nitrogen incorporated into the body on the test diet However direct measurement of Nr is essentially impossible. It will typically be measured indirectly from nitrogen excretion in urine. Faecal excretion of nitrogen must also be taken into account - this part of the ingested protein is not absorbed by the body and so not included in the calculation of BV. An estimate is used of the amount of the urinary and faecal nitrogen excretion not coming from ingested nitrogen. This may be done by substituting a protein-free diet and observing nitrogen excretion in urine or faeces, but the accuracy of this method of estimation of the amount of nitrogen excretion not coming from ingested nitrogen on a protein-containing diet has been questioned.
Different crystalline forms of an element are called allotropes. Some allotropes, particularly those of elements located (in periodic table terms) alongside or near the notional dividing line between metals and nonmetals, exhibit more pronounced metallic, metalloidal or nonmetallic behaviour than others. The existence of such allotropes can complicate the classification of the elements involved. Tin, for example, has two allotropes: tetragonal "white" β-tin and cubic "grey" α-tin. White tin is a very shiny, ductile and malleable metal. It is the stable form at or above room temperature and has an electrical conductivity of 9.17 × 104 S·cm−1 (~1/6th that of copper). Grey tin usually has the appearance of a grey micro-crystalline powder, and can also be prepared in brittle semi-lustrous crystalline or polycrystalline forms. It is the stable form below 13.2 °C and has an electrical conductivity of between (2–5) × 102 S·cm−1 (~1/250th that of white tin). Grey tin has the same crystalline structure as that of diamond. It behaves as a semiconductor (as if it had a band gap of 0.08 eV), but has the electronic band structure of a semimetal. It has been referred to as either a very poor metal, a metalloid, a nonmetal or a near metalloid. The diamond allotrope of carbon is clearly nonmetallic, being translucent and having a low electrical conductivity of 10−14 to 10−16 S·cm−1. Graphite has an electrical conductivity of 3 × 104 S·cm−1, a figure more characteristic of a metal.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.